insulin glargine
DrugOther names: Lantus Insulin
NCT Number: NCT02006342
To determine if co-administration of subcutaneous (SQ)Insulin glargine in combination with intravenous (IV) insulin decreases the time to resolution of ketoacidosis and requirement for ICU admission compared to IV insulin with delayed administration of SQ glargine for the treatment of diabetic ketoacidosis (DKA).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Lyndon B Johnson Hospital, Houston, Texas, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Lantus Insulin
Time frame: Participants monitored from hospital admission to discharge, an average of 4 days
Anion Gap is a measure of acidosis that results from decompensated Diabetes Mellitus. Acidosis is the result of the body being unable to utilize glucose for energy production and instead uses fatty acid metabolism resulting in ketone formation. Anion Gap is a surrogate measure for the level of ketones resulting in the excess acid production. Results reported are adjusted for initial anion gap, etiology of diabetic ketoacidosis, and comorbidities.
Time frame: Participants followed for the duration of the Emergency Department stay, an expected average of 12 hours
The goal was to determine if the amount of patients admitted to the ICU could be reduced by providing more efficient resolution of the critical condition which is the acidosis.
Time frame: Participants monitored from hospital admission to discharge, an average of 4 days
Determine the amount of time patient is admitted to the intensive care unit with the goal of assessing if more efficient correction of the acidosis results in decreased time in the intensive care unit for the patients.
Time frame: Participants monitored from hospital admission to discharge, an average of 4 days
Hospital length of stay was determined to assess whether a more efficient correction of the acidosis will result in decreased time that the patient is admitted to the hospital. Results reported are adjusted for age, hospital site, and etiology of diabetic ketoacidosis.
Time frame: Participants monitored during the 24 hours after anion gap closure
To determine whether it is safe to administer both IV and subcutaneous insulin, it is important to assure that patient's glucose does not drop to critically low level and lead to adverse events. Hypoglycemia was defined as less than or equal to 60mg/dL during 24 hours after anion gap closure.
Anion Gap is a measure of acidosis that results from decompensated Diabetes Mellitus. Acidosis is the result of the body being unable to utilize glucose for energy production and instead uses fatty acid metabolism resulting in ketone formation. Anion Gap is a surrogate measure for the level of ketones resulting in the excess acid production.
The University of Texas Health Science Center, Houston
Other
Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis: A Pilot Study
Acronym: GT-COG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03717896
Acid-Base Imbalance, Acidosis
Boston, Massachusetts, United States
View Trial DetailsNCT05439928
Acid-Base Imbalance, Acidosis
New York, United States
View Trial DetailsNCT06327737
Acid-Base Imbalance, Acidosis
Antalya, Turkey (Türkiye)
View Trial DetailsNCT06251895
Acid-Base Imbalance, Acidosis
Kuwait, Al Jahra Governorate
View Trial Details